Daclizumab: A Review in Relapsing Multiple Sclerosis

Drugs

Volumn 77, Issue 4, 2017, Pages 447-458

  Shirley, Matt ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ARTICLE; DEPRESSION; DISABILITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LIVER DISEASE; LYMPHADENITIS; LYMPHADENOPATHY; MULTIPLE SCLEROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SKIN DISEASE; DRUG TOLERANCE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG TOLERANCE; HUMANS; IMMUNOGLOBULIN G; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 85013129835     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-017-0708-2     Document Type: Article

References (53)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.
2. Nylander A, Hafler DA. Multiple sclerosis. J Clin Investig. 2012;122(4):1180–8.
3. National Multiple Sclerosis Society. What is MS? 2016. http://www.nationalmssociety.org/What-is-MS. Accessed 23 Sept 2016.
4. National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. 2014. https://www.nice.org.uk/guidance/cg186. Accessed 20 Jan 2017.
5. Rejdak K, Jackson S, Giovannoni G. Multiple sclerosis: a practical overview for clinicians. Br Med Bull. 2010;95:79–104.
6. Ali R, Nicholas RSJ, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs. 2013;73(7):625–50.
7. Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518.
8. Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs. 2011;25(1):37–52.
9. Ingwersen J, Aktas O, Hartung H-P. Advances in and algorithms for the treatment of relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016;13(1):47–57.
10. Fontoura P. Monoclonal antibody therapy in multiple sclerosis: paradigm shifts and emerging challenges. MAbs. 2010;2(6):670–81.
11. European Medicines Agency. Zinbryta: summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 20 Jan 2017.
12. US FDA. Zinbryta (daclizumab) injection: US prescribing information. 2016. http://www.fda.gov. Accessed 20 Jan 2017.
13. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013;10(1):55–67.
14. ®. MAbs. 2016;8(7):1417–24.
15. c receptors. Science. 2005;310(5751):1159–63.
16. bright NK cells. J Immunol. 2010;185(2):1311–20.
17. Huss DJ, Mehta DS, Sharma A, et al. In vivo maintenance of human regulatory T cells during CD25 blockade. J Immunol. 2015;194(1):84–92.
18. bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis. Br J Clin Pharmacol. 2016;82(5):1333–42.
19. Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med. 2011;17(5):604–9.
20. Minocha M, Tran JQ, Sheridan JP, et al. Blockade of the high-affinity interleukin-2 receptors with daclizumab high-yield process: pharmacokinetic/pharmacodynamic analysis of single- and multiple-dose phase I trials. Clin Pharmacokinet. 2016;55(1):121–30.
21. bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA. 2006;103(15):5941–6.
22. European Medicines Agency. European public assessment report: Zinbryta (daclizumab). 2016. http://www.ema.europa.eu. Accessed 19 Jan 2017.
23. bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e65.
24. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9884):2167–75.
25. Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014;13(5):472–81.
26. Lin YC, Winokur P, Blake A, et al. Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Ann Clin Transl Neurol. 2015;2(5):445–55.
27. Perry JSA, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med. 2012;4(145):145ra06.
28. Gillard GO, Saenz SA, Huss DJ, et al. Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy. J Neuroimmunol. 2016;294:41–5.
29. Oh U, Blevins G, Griffith C, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol. 2009;66(4):471–9.
30. Mehta D, Reister K, Sheridan J, et al. Rapid, sustained and reversible pharmacodynamics of DAC HYP in MS patients supports mechanism of action via modulation of the IL-2 pathway [abstract no. P972]. Mult Scler. 2014;20(Suppl 1):491–2.
31. Lin YC, Winokur P, Blake A, et al. Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination. Neurol Neuroimmunol Neuroinflamm. 2016;3(1):e196.
32. Mehta L, Umans K, Ozen G, et al. Immune response to seasonal influenza vaccine in relapsing-remitting multiple sclerosis patients on long-term daclizumab in a prospective, open-label, single-arm study. Int J MS Care. 2017. doi:10.7224/1537-2073.2016-026.
33. Diao L, Hang Y, Othman AA, et al. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers and subjects with multiple sclerosis: analysis of phase I-III clinical trials. Clin Pharmacokinet. 2016;55(8):943–55.
34. Othman AA, Tran JQ, Tang MT, et al. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. Clin Pharmacokinet. 2014;53(10):907–18.
35. Tran JQ, Othman AA, Mikulskis A, et al. Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis. Clin Pharmacol. 2016;8:9–13.
36. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373(15):1418–28.
37. Gold R, Radue E-W, Giovannoni G, et al. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016;16:117.
38. Kappos L, Cohan S, Arnold DL, et al. Interim report on the safety and efficacy of long-term daclizumab HYP treatment for up to 5 years in EXTEND [abstract no. P653 plus poster]. In: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. 2016.
39. Rose J, Wiendl H, Arnold D, et al. Daclizumab HYP reduced brain MRI lesion activity compared with interferon beta-1a: results from the DECIDE study [abstract no. P7.252]. Neurology. 2015;84(14 Suppl):P7.252.
40. Giovannoni G, Greenberg S, Tsao C, et al. Efficacy of daclizumab HYP across subgroups of varying relapsing-remitting multiple sclerosis disease severity: results from the SELECT study [abstract no. EP1152]. J Neurol. 2014;261(Suppl 1):S94.
41. Wiendl H, Havrdova E, Rose J, et al. Daclizumab HYP versus interferon β-1a across patient demographic and disease activity subgroups in the DECIDE phase 3 study [abstract no. P4.007]. Neurology. 2015;84(14 Suppl):P4.007.
42. Wiendl H, Kappos L, Selmaj K, et al. Daclizumab high-yield process (DAC HYP) vs. interferon beta-1a in patients with highly active disease: DECIDE study results [abstract no. O1218]. Eur J Neurol. 2015;22(Suppl 1):50.
43. Giovannoni G, Ziemssen T, Ma W, et al. Daclizumab HYP efficacy on disease outcome measures using an expanded definition of highly active relapsing-remitting multiple sclerosis: results from SELECT and DECIDE [abstract no. P31133 plus poster]. Eur J Neurol. 2016;23(Suppl 2):663.
44. Havrdova E, Kappos L, Selmaj K, et al. The efficacy and safety of daclizumab high-yield process (DAC HYP) in patients previously treated with disease-modifying therapies: subgroup analyses from the DECIDE study [abstract no. P1158]. Eur J Neurol. 2015;22(Suppl 1):152.
45. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840–6.
46. Phillips GA, Wyrwich KW, Guo S, et al. Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening. Mult Scler. 2014;20(13):1753–60.
47. Phillips G, Guo S, Bender R, et al. Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: results from the SELECT trial. Mult Scler Relat Disord. 2016;6:66–72.
48. Liu Y, Vollmer T, Havrdova E, et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2017;11:18–24.
49. Giovannoni G, Radue E-W, Havrdova E, et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol. 2014;261(2):316–23.
50. Giovannoni G, Kappos L, Gold R, et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies. Mult Scler Relat Disord. 2016;9:36–46.
51. Krueger JG, Kircik L, Hougeir F, et al. Cutaneous adverse events in the randomized, double-blind, active-comparator DECIDE study of daclizumab high-yield process versus intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. Adv Ther. 2016;33(7):1231–45.
52. Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273–9.
53. European Medicines Agency. Novantrone review. 2016. http://www.ema.europa.eu. Accessed 19 Jan 2017.